Apatinib, a small-molecule inhibitor of VEGFR-2, has attracted much attention due to its encouraging anticancer activity in thirdline clinical treatment for many malignancies, including non-small cell lung cancer (NSCLC). Its usage in second-line therapy with chemotherapeutic drugs is still under exploration. In this study we investigated the antitumor effect of apatinib combined with docetaxel against NSCLC and its cellular pharmacokinetic basis. A549 xenograft nude mice were treated with apatinib (100 mg/kg antitumor effect of docetaxel and alleviated docetaxel-induced liver damage as well as decreased serum transaminases (ALT and times) without enhancing the docetaxel concentration in the serum, heart, liver, lung and kidney. Furthermore, apatinib decreased of docetaxel were investigated in A549 and A549/DTX (docetaxel-resistant) cells in vitro. A cellular pharmacokinetic study revealed cells. Consequently, the IC 50 cells. These results demonstrate that apatinib has potential for application in second-line therapy combined with docetaxel for NSCLC patients, especially for docetaxel-resistant or multidrug-resistant patients.
Introduction
Apatinib, a highly selective small-molecule tyrosine kinase inhibitor of VEGFR2 [1] , was approved in China in 2014 as a third-line treatment for patients with advanced gastric cancer. Apatinib can inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvascular density. Apatinib is now under study in phase II and III clinical trials for other cancer types, such as non-small cell lung cancer (NSCLC), breast cancer and advanced hepatocellular carcinoma [2] [3] [4] . Apatinib has attracted much attention due to its encouraging anticancer activity clinically [5, 6] . However, anti-angiogenic agents have shown modest survival benefits because they exert cytostatic activity rather than cytotoxicity. In recent years, aggressive recurrence and accelerating metastatic tumor growth were observed after the discontinuation of sunitinib in xenograft nude mice or clinical trials [7, 8] . In addition, no prolonged overall survival (OS) was found in some patients because of acquired resistance [9, 10] . Therefore, the combination of two or more anti-tumor agents is a more effective strategy to overcome the acquired resistance and limited [11, 12] . Lung cancer is the most common primary malignant tumor and leading cause of cancer mortality in the world [13] . A randomized phase III clinical trial assessed the role of ramuci-rumab and docetaxel versus docetaxel/placebo in patients demonstrated an OS advantage and progression-free survival (PFS) prolongation with the addition of ramucirumab [14] . In addition to neutralizing antibodies, the role of anti-angiogenic receptor tyrosine kinase inhibitors (TKIs), including sorafenib [15, 16] , cediranib [17] , sunitinib [18] , vandetanib [19, 20] and nintedanib [21, 22] , in the treatment of NSCLC has been the subject of multiple clinical trials. The results of the LUME -Lung 1 the combination of docetaxel plus nintedanib, indicating that nintedanib in combination with docetaxel was an effective second-line option for patients with advanced NSCLC [23] . Many small-molecule compounds in combination with cytotoxic drugs in the treatment of cancer. However, the efficacy and -therapeutic drugs are still under investigation.
Previous studies have shown that apatinib significantly increased the intracellular accumulation of doxorubicin and rhodamine 123 in drug-resistant cells and enhanced the antitumor effect of paclitaxel in P-gp resistant KBv200 cancer cell xenografts [24] . Tong et al also found an enhanced effect of doxorubicin in combination with apatinib in K562/ADR xenograft mice [25] . The present study focused on the antitumor effects of apatinib combined with docetaxel on NSCLC in vitro and in vivo. The effects of apatinib on the antitumor activity or toxic effect of docetaxel were investigated. Additionally, the material basis of the apatinib and docetaxel combination was explored from the perspective of cellular pharmacokinetics.
Materials and methods

Chemicals and reagents
Apatinib and docetaxel were obtained from Jiangsu Hengrui Medicine Co (Lianyungang, Jiangsu, China). Methanol was HPLC grade and purchased from Merck (Darmstadt, Germany). Purified water was produced using a Milli-Q system purchased from Millipore (Bedford, MA, USA). The test kits for the content of serum transaminases (ALT and AST), alkaline phosphatase (ALP), creatinine (Cr), urea nitrogen (BUN) and phosphocreatine kinase (CK) were purchased from Nanjing Jiancheng Biology Research Institute (Nanjing, Jiangsu, China). Fetal bovine serum and 100 U/mL penicillin and streptomycin were purchased from Invitrogen (Carlsbad, CA, USA). Digoxin, 7-ethyl-10-hydroxycamptothecin (SN-38) and purchased from Sigma (St Louis, MO, USA). Primary antibodies against P-gp and ATPase Na + /K + were purchased from Abcam (Cambridge, MA, USA).
Animals and treatments
Male athymic nude mice (BALB/c-nu/nu) aged 4-6 weeks and weighing 18-22 g were purchased from Shanghai Slike Experimental Animals Co (Shanghai, China) and were used free conditions. The animals were cared for according to the Animal Facility Guidelines of the China Pharmaceutical University. When the tumor volumes were more than 100 mm 3 , these A549 xenograft mice were randomized into four groups (n=6 per group): (a) saline (every four days for five times); (b) apatinib (100 mg/kg, every day for 20 days); (c) docetaxel (8 mg/kg, every four days for five times); (d) apatinib (100 mg/kg,) plus docetaxel (8 mg/kg, every four days for five times). Docetaxel and apatinib were administered at intervals and were not administered on the same day in the combined group. Docetaxel was intraperitoneally administered on the for three consecutive days. From day 5, apatinib was administered four times (a diagram is shown in Figure 1B ). The body weight of the animals as well as the long (a) and short diameters (b) were recorded every day. Tumor volume (TV) was calculated as: a/2×b×b. On the last day (day 21), to avoid tran--ment with docetaxel for 0.5 h without apatinib. Next, plasma and tissues were collected and stored at -80 °C until analysis.
Hematoxylin and eosin staining and ALT and AST assays Fresh lung, heart, liver and kidney were fixed in 10% phosphate-buffered formalin immediately and were implanted detect the concentrations of ALT, AST, ALP, Cr, BUN and CK according to the manufacturer's instructions.
Cell culture
Human colon carcinoma Caco-2 cells, human non-small cell lung cancer A549 cells and docetaxel-resistant A549 cells (A549/DTX cells) were purchased from Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and were cultured in DMEM and RPMI-1640, respectively, both supplemented with 10% fetal bovine serum and 100 U/mL penicillin and streptomycin at 37 °C with 5% carbon dioxide.
Cell viability assay A549 and A549/DTX cells (2×10 5 cells/mL) were cultured in 96-well plates for the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) colorimetric assay. After 24 h, the control group was incubated with medium containing dimethyl sulfoxide (DMSO). A549 cells were incubated with various concentrations of docetaxel (0.000625, 0.00125, A549/DTX cells were also treated with various concentrations at 37 °C for 48 h. A series of concentrations of apatinib (0.125, -toxicity of A549 and A549/DTX cells. The concentrations of apatinib and docetaxel required to inhibit the growth of A549 and A549/DTX cells by 50% (IC 50 ) were calculated using the SPSS software. In addition, the fold reversal factor of multidrug resistance (MDR) was calculated using the ratio of the IC 50 of docetaxel in the absence of apatinib to that in the presence of apatinib or LY335979.
Accumulation of digoxin, SN-38, CDCF and docetaxel in Caco-2 cells Caco-2 cells were seeded on 24-well cell culture plates evenly. After reaching 80%-90% confluency, the cultured cells were treated with 1 mL of Hanks' solution containing digoxin (a -ing of the accumulations of SN-38 (a specific substrate of -of BCRP and MRP2). In addition, cultured cells were treated with 1 mL Hanks' solution containing three concentrations of of P-gp, MRP2 and BCRP to investigate whether docetaxel was the substrate of ABC transporters. After incubation for 2 h in a 37 °C incubator, retention was stopped. Cells were lysed in 500 the cell suspension was collected for the measurement of protein concentrations using the BCA protein assay kit. Digoxin, SN-38 and docetaxel were determined by LC-MS/MS, and Effect of apatinib on the uptake of docetaxel in A549 and A549/ DTX cells Similar to Caco-2 cells, A549 and A549/DTX cells were treated -bation for 2 h in a 37 °C incubator, the retention was stopped. We next investigated the uptake progress (0, 0.083, 0.25, 0.5, 1, 2, 4 h) of docetaxel in the absence and presence of apatinib or LY3359799. Cell collection and sample handling were performed as described previously for the drug accumulation study.
DTX cells
Cells were treated as in the docetaxel uptake study and were incubated in a 37 °C incubator for 2 h. Next, each well was washed twice with 1 mL of Hanks' solution to remove impurimedium was added. After incubation for another 0, 0.25, 0.5, the uptake study.
Effect of apatinib on the subcellular distribution of docetaxel in A549 and A549/DTX cells After 7 days of culture, the cells were treated with docetaxel 3 times with Hanks' solution. Next, the cells were scraped into an Eppendorf tube and centrifuged at 1000 r/min for 5 min.
The cells were resuspended in 1 mL of lysis buffer and milled with a glass homogenizer 35-40 times. The cell nucleus, mitochondria and cytoplasm were isolated using the KeyGen Mitochondria/Nuclei Isolation Kit according to the manufacturer's instructions.
Quantitative real-time PCR Total RNA was extracted from tumor and intestine tissues using the RNAiso Plus reagent according to the manufacturer's protocol. Reverse transcription of 500 ng of total RNA to evaluate MDR1, MRP2 and BCRP in tumor tissue was performed using SuperScript II Reverse Transcriptase (Invitrogen). Quantification of reverse transcription PCR analysis was performed using SYBR green PCR Master Mix and a MyIQ real-time PCR cycler (BioRad, Veenendaal, The Netherlands), and the expression of the targets was normal- 
Western blot analysis
10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and were transferred to polyvinylidene blocking with 5% non-fat milk for 1 h, the membrane was incubated with primary antibodies against P-gp (1:1000) and ATPase Na + /K + (1:10000) overnight at 4 °C, followed by incubation with horseradish peroxidase (HRP)-linked secondary antibodies for 2 h at 37 °C. The signals were detected using an enhanced chemiluminescence kit (Thermo Fisher Scientific, MA, USA) and were obtained using the ChemiDoc XRS+ System (Bio-Rad, Hercules, CA, USA). The intensity of the bands Sample preparation and analysis of methanol containing paclitaxel as an internal standard proteins. Tumor, lung, heart, liver and kidney tissues were homogenized in physiological saline (1:10 w/v). After centrifuwas injected into the LC-MS/MS system for analysis. The LC-MS/MS system consisted of the Shimadzu HPLC system 20A and AB API4000 quadrupole mass spectrometer with an electrospray ionization (ESI) interface.
Separation of docetaxel was carried out using a Luna C18 40 °C. The mobile phase consisted of solvent A (0.1% formic acid and 2 mg/L sodium acetate) and solvent B (methanol) with the following gradient conditions: the initial proportion was 40% B, followed by a hold for 0.5 min, an increase to 75% B over 0.5 min, an increase to 90% B over 2 min, maintenance for 3 min, a decrease to 40% B over 1 min, and termination at -eter was used in the positive electrospray ionization (ESI) mode. The MS parameters were as follows: ion spray voltage, 5500 V. Multiple reaction monitoring (MRM) was performed at m/z for paclitaxel. The collision energies of docetaxel and paclitaxel were 35 eV and 33 eV, respectively. The ion spray voltage was set to 5500 V, and the source temperature was maintained at 550 °C. Detection of digoxin and SN-38 was performed as previously described [26, 27] . Intracellular accumulation of CDCF was detected using the microplate reader Powerwave 200 (Bio-Tek Instruments, VT, USA). The excitation wavelength and emission wavelength were 470 and 529 nm, respectively.
Data analysis
All values are expressed as the mean±SEM. Statistical analysis was analyzed by one-way ANOVA. The difference was considered to be statistically significant if the probability value was less than 0.05 (P<0.05).
Results
Synergistic anti-tumor effect of apatinib in combination with docetaxel in A549 xenograft mice the treatment of NSCLC was evaluated in nude mice bearing A549 xenografts. The tumor growth curves showed that growth was slower in the treated group than in the vehicle group ( Figure 1A and B) . On day 20, the average tumor volume (TV) of the vehicle group was 456.42±69.79 mm 3 , whereas the TVs were 181.00±29.75 mm 3 in the apatinib group, 248.91±42.29 mm 3 in the docetaxel group, and 100.88±10.10 mm 3 in the apatinib+docetaxel group. The tumor inhibitory rate of the combined treatment group was higher than that of decrease in the body weight of mice was also observed in the docetaxel and combination groups but not in the apatinib group ( Figure 1D ), indicating the incidence of toxic side effects of docetaxel to a certain extent.
Protective effect of apatinib on liver damage induced by docetaxel in A549 xenograft mice Enhancement of the chemotherapeutic effect of docetaxel may increase the risk of side effects. Therefore, we investigate the side effects of docetaxel with or without apatinib on the Figure 2A , histopathological abnormality was not evident in the lung, heart, and kidney after treatment with the drugs, indicating both apatinib and docetaxel caused little damage to these tissues. In addition, and BUN) and cardiac function indicators (CK) in serum, consistent with the histopathological results ( Figure 2C and 2D) . However, liver injury, such as inflammatory cell infiltration
Moreover, the indicators of liver function (ALT and AST) were increased after administration of docetaxel ( Figure 2B ), decreased the amount of ALT and AST caused by docetaxel. These results suggest that the combination of apatinib and docetaxel is an effective treatment regimen with reduced side effects.
Apatinib enhances the tumor concentration of docetaxel without in A549 xenograft mice The distribution of docetaxel in tumor and other main tissues were investigated to clarify whether efficacy enhancement and liver injury alleviation by apatinib were related to the pharmacokinetic changes in docetaxel. Apatinib significantly increased the content of docetaxel in tumors, up to 1.77 Figure 3B and 3C).
Apatinib decreases P-gp expression in tumors induced by docetaxel in A549 xenograft mice Docetaxel and apatinib are substrates of P-glycoprotein [28] , and continuous treatment with docetaxel can induce multidrug resistance via P-gp up-regulation. The gene expression tissues were determined. Our data showed that gene expression of P-gp in tumor tissue was elevated by 2.13 times compared with that in the vehicle group after administration of docetaxel, a level that was significantly decreased by combined treatment with apatinib (vs the docetaxel group, P<0.01) ( Figure 4A ). However, the gene expression levels of BCRP and MRP2 were not significantly changed after drug treatments. Moreover, the change in P-gp protein expression in tumors was consistent with that in gene expression ( Figure 4B ).
Because apatinib was orally administered, the gene and pro--sue were determined. As shown in Figure 4C and 4D, apatinib treatment with or without docetaxel did not affect the expression of P-gp, MRP2 and BCRP.
Increased accumulation of docetaxel induced by apatinib mainly occurs through inhibition of P-gp Next, we further investigated the effect of apatinib inhibition on the efflux transporters in vitro. Digoxin, SN-38 and CDCF were used as specific substrates for P-gp, BCRP and MRP2, respectively. We found that apatinib could effectively increase the intracellular concentration of digoxin and SN-38, but not that of CDCF, indicating that apatinib could significantly inhibit the function of P-gp and BCRP, but had no effect on MRP2 ( Figure 5A ). We also studied the effect of specific inhibitors of P-gp, MRP2 and BCRP on docetaxel accumulation in Caco-2 cells. Only LY335979 and Ko143 significantly increased the accumulation of docetaxel (up to 5.2 and 2.3 times), indicating that docetaxel was the main substrate of P-gp and BCRP ( Figure 5B ). Because the anti-tumor effect was studied in A549 xenograft mice, we used A549 cells (sensitive to docetaxel) and A549/DTX cells (resistant to docetaxel, with highly expressed P-gp) for further cellular pharmacokinetics research. As shown in Figure 5C and 5D, the concentration of docetaxel was approximately three times higher in A549 cells than in A549/DTX cells. Because docetaxel is the substrate of of P-gp and BCRP on the cellular accumulation of docetaxel in A549 and A549/DTX cells, respectively. The data showed that apatinib significantly increased the content of docetaxel in A549/DTX cells, but not in A549 cells, a finding that was -tor of BCRP had no effect on the accumulation of docetaxel in either A549 cells or A549/DTX cells ( Figure 5C and 5D ). Taken together, these results suggest that P-gp plays an important role in increasing the content of docetaxel by apatinib treatment in A549 xenograft mice.
Apatinib increases the cellular accumulation and subcellular distribution of docetaxel in A549/DTX cells but not in A549 cells
Because P-gp is crucial in the increased concentration of docetaxel in the above in vivo and in vitro results, we used LY335979 as a positive control to investigate whether apatinib could affect the cellular pharmacokinetic behavior of docetaxel in A549 and A549/DTX cells. In A549/DTX cells, apatinib and LY335979 both significantly enhanced the accumulation of docetaxel in a time-dependent manner ( Figure 6B ). The content of docetaxel in A549/DTX cells was rapidly decreased once apatinib or LY335979 was withdrawn and reached a relatively stable level 1 h later, a trend that was still higher in the combined treatment groups than in the docetaxel group (Figure 6D) . However, the effect of apatinib or LY335979 on the cellular accumulation of docetaxel was not observed in sensitive A549 cells ( Figure 6A and 6C) .
The drug concentration around the target determines its action. Docetaxel, as a microtubule-targeting chemotherapeutic drug, exerts its efficacy in the cytosol. Therefore, the distribution of docetaxel in subcellular organelles (including in the cytosol, nuclei and mitochondria) was detected. The AUC 0-2 h of docetaxel in the cytosol was the highest among these subcellular organelles in either A549 or A549/DTX cells ( Figure 7G and 7H) . Similar to the uptake results, combined treatments with apatinib or LY335979 induced a rapid increase in the subcellular accumulation of docetaxel in the first 0.5 h in A549/DTX cells ( Figure 7B, 7D and 7F) . Notably, the AUC 0-2 h of docetaxel in the cytosol was increased by 6.38 times with apatinib treatment. However, higher accumulation was not observed in the presence of apatinib or LY335979 in sensitive A549 cells ( Figure 7A, 7C and 7E) . Table 1 . LY335979 was used as the positive control. The IC 50 value of docetaxel -DTX cells by 21.00-fold, a trend that was better than the combined treatment with LY335979. Interestingly, we also found that apatinib slightly enhanced the cytotoxicity of docetaxel in A549 cells.
Discussion
ATP-binding cassette (ABC) transporters, such as P-gp, MRP and BCRP, are often reported to be highly expressed in cancer, cancer cells and reducing their cytotoxic effect. Additionally, long-term chemotherapy can lead to multi-drug resistance of cytotoxic effects in cancer cells, significantly decreasing the efficacy of cancer chemotherapy. Several anti-angiogenic receptor tyrosine kinase inhibitors (TKIs) were found to interact with major ABC transporters, including P-gp, MRP and BCRP [29] significantly inhibit the function P-gp and BCRP, increas- [33] . Liu et al found that Astragalus polysaccharides could protect against the hepatotoxicity induced by frequently used chemical therapy agents, including docetaxel [34] . However, to the best of our knowledge, no other study has reported on the protective effect of combined chemotherapy against docetaxel-induced liver damage. Therefore, alleviation of docetaxel-induced liver injury may be one of the advantages of the combined use of apatinib and docetaxel in clinical NSCLC chemotherapy.
Our pharmacokinetics data showed that apatinib significantly increased the distribution of docetaxel in tumors but exerted no obvious effect on the docetaxel concentrations in the plasma, kidney, lung, heart and liver. This result further confirmed that apatinib enhanced the anti-tumor effect of docetaxel but did not increase docetaxel-induced injury to other organs. P-gp, MRP2 and BCRP are three major ATPdependent efflux transporters that reduce the intracellular content of many chemotherapeutic agents, possibly resulting in multi-drug resistance [35] . Our results also showed that multiple administrations of docetaxel induced upregulation of P-gp in tumors, which might be a key mediator of the acquisition of docetaxel resistance [36] . Zhu et al also found that acquired docetaxel resistance was mediated by the overexpression of P-gp in prostate cancer, while targeting the expression of P-gp could overcome docetaxel resistance by inducing more apoptotic cell death [28] . The present study found that combined treatment with apatinib down-regulated the expression of P-gp induced by docetaxel, which is in accordance with the increased tumor distribution of docetaxel. Although apatinib was also reported to be a substrate of P-gp, fortunately, con- ing their intracellular substrate accumulation [30] [31] [32] . Apatininb was also found to increase intracellular accumulation of DOX and Rho 123 in MDR cells [24] . In this study, we investigated whether apatinib could be used in combination with docetaxel in vivo and in vitro, providing more choices for patients with advanced NSCLC.
The present study showed that apatinib enhanced the inhibitory effect of docetaxel on the tumor growth and volume. Pathological data also demonstrated that the lung, heart and kidney were not significantly affected by the drugs in either single or combined treatment. Interestingly, liver damage was tinuous oral administration of apatinib in mice did not induce upregulation of P-gp in tumor or intestinal tissue. Several studies have also demonstrated that apatinib could reverse P-gp-and BCRP-mediated multidrug resistance by inhibiting their transport function but did affect their expression [25, 37] . Our in vitro data from Caco-2 cells also showed that docetaxel was the substrate of P-gp and BCRP, the function of which was significantly inhibited by apatinib. However, increased accumulation of docetaxel by apatinib only occurred in A549/ DTX cells, which had a similar effect as the P-gp inhibitor LY335979 rather than the BCRP inhibitor Ko143. Taken together, the data indicate that the increased concentration of docetaxel in tumors mainly occurs via the inhibitory effect of apatinib on P-gp.
Cellular pharmacokinetics is an emerging branch of traditional pharmacokinetics and has attracted attention for the evaluation and improvement of anticancer therapy. A previous study showed that 20(S)-ginsenoside Rh2 (20(S)-Rh2) significantly increased the rate and amount of adriamycin entering adriamycin-resistant MCF-7 cellular or subcellular organelles and aggravated adriamycin-induced apoptosis [38] . Yuan et al also demonstrated the reversal effect of cinobufagin on P-gp-mediated resistance of anticancer drugs regarding cellular pharmacokinetics [39] . Next, A549/DTX cells were used to study whether apatinib could make a favorable cellular pharmacokinetic change in docetaxel-resistant cells that might subsequently play a role in reversing drug resistance. Obviwere found in the presence of apatinib or LY335979 in A549/ DTX cells and subcellular organelles, especially in the target cytosol. In the present study, our data also showed that the apatinib concentration dependently enhanced the cytotoxicity of docetaxel in A549/DTX cells. Interestingly, apatinib also tended to increase the sensitivity of docetaxel in A549 docetaxel by apatinib may occur via mechanisms other than the increased cellular concentration. Overall, our data provide proof of the effectiveness of the combination of apatinib and docetaxel for treating NSCLC patients, especially patients with acquired docetaxel resistance.
Conclusion
The present study demonstrated that apatinib enhanced the anti-tumor effect of docetaxel and minimized docetaxelinduced side effects in the liver, effects that were closely related to the increased distribution of docetaxel and decreased expression of P-gp in tumors. In vitro, apatinib elevated the accumulation of the cellular/subcellular distribution in docetaxel-resistant A549/DTX cells rather than in A549 cells, and the cytotoxicity of docetaxel was also enhanced by apatinib, especially in A549/DTX cells. Our data are supportive of the clinical combined treatment of apatinib and docetaxel for treating NSCLC, especially for multidrug-resistant patients.
